



Background and Aims: The molecular alterations that underlie carcinoid tumor pathogenesis remain poorly 
defined.  The homeobox gene Hoxc6 was highly upregulated in human gastrointestinal carcinoid tumors, and 
we sought to define its pathogenic role.
Methods: The functional and physical properties of Hoxc6 were investigated by establishing carcinoid cells 
that stably overexpressed Hoxc6 or were deficient in Hoxc6.  Cellular proliferation assays, luciferase reporter 
assays, western blotting, and immunoprecipitation were performed. 
Results: Expression of Hoxc6 in cultured human BON1 carcinoid cells enhanced their proliferation, and 
knock-down of Hoxc6 inhibited their growth.  Hoxc6 activated the oncogenic AP-1 signaling pathway through a 
physical interaction with JunD.  Mutations in the homeodomain of Hoxc6 blocked this interaction and inhibited 
proliferation of carcinoid cells.  
Conclusions: A novel molecular pathway has been identified that links Hoxc6 with oncogenic signaling 
through the AP-1 pathway in carcinoid tumorigenesis. 
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Introduction
Carcinoid tumors are neuroendocrine neoplasms 
that can arise in multiple organ sites but are most 
commonly localized to the gastrointestinal tract 1. 
They are typically slow-growing, well-differentiated 
tumors that secrete 5-hydroxytryptamine (serotonin), 
and excess levels can result in the clinical carcinoid 
syndrome 2.  Gastrointestinal carcinoids are often 
classified together with neuroendocrine tumors of 
the pancreas, as they share many clinical and bio-
logical features.  However, key insights into their 
underlying molecular pathogenesis are lacking.
Individuals with the Multiple Endocrine Neoplasia 
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Type 1 syndrome are at high risk for the development 
of neuroendocrine tumors of the pancreas and pitu-
itary, as well as parathyroid gland hyperplasia and 
gastric carcinoids.  The MEN1 tumor suppressor gene 
that underlies the syndrome was cloned in 1997 3. 
MEN1 also plays a role in sporadic pancreatic neu-
roendocrine tumors and gastrointestinal carcinoids, 
but only a subset of these sporadic tumors harbors 
MEN1 mutations 4.  The MEN1 gene product, menin, 
has diverse functions 5, and most recently has been 
demonstrated to regulate gene transcription through 
interactions with a histone methyltransferase com-
plex 6, 7.  Some of the targets of menin include the 
homeobox genes Hoxc6 and Hoxc8 6 as well as the 
cell cycle inhibitors p18 and p27 8, 9.
Homeobox (Hox) genes belong to the homeoprotein 
family of transcription factors that are developmental 
regulators of growth, patterning, and differentiation. 
There are 4 clusters of Hox genes (HOXA-D), and 
Hox proteins contain a homeodomain that consists 
of three helices separated by a short loop.  Helix III 
(the C-terminal helix) contacts A/T-rich domains of 
DNA in the regulatory regions of many genes 10. 
Because most homeobox proteins have similar DNA 
binding specificity in vitro, the timing of expression 
as well as the interactions between Hox proteins 
and other transcriptional regulators are likely to be 
critical for their functional specificity.  Deregulated 
expression of Hox genes has been reported in many 
tumors, including lung, breast, ovarian, sarcoma, 
and leukemia 10.  The specific mechanisms by which 
Hox genes contribute to the tumorigenic phenotype 
are incompletely described.  In some cases, they 
may function as transcription factors that stimulate 
the expression of growth factors, such as Hoxb7-
mediated upregulation of fibroblast growth factor in 
melanomas 11.  Overexpression of Hoxc6 is observed 
in human prostate cancer, where it functions to in-
hibit apoptosis 12, 13. 
Because of the link between the Hoxc6 and 
Hoxc8 gene clusters and the MEN1 gene 6, we were 
curious whether expression of these Hox genes was 
altered in human neuroendocrine tumors.  Previ-
ous DNA microarray studies indicated that Hoxc6 
mRNA was strongly upregulated in gastrointestinal 
carcinoid tumors but not in closely related pancreatic 
neuroendocrine tumors (in press).  We now verify 
these findings and demonstrate that expression of 
Hoxc6 stimulated the growth of carcinoid cells in 
vitro.  Hoxc6 enhanced signaling through the AP-1 
pathway, and this was mediated by a novel interac-
tion between Hoxc6 and the JunD component of 
AP-1.  These findings link a developmental regulator 
to an oncogenic signaling pathway.  In addition to 
providing an important new insight into the patho-
genesis of carcinoid tumors, these studies point to 




BON1 cells (a human pancreatic carcinoid cell 
line) were utilized to generate cells stably overex-
pressing Hoxc6-Variant1, Hoxc6-Variant 2, or an 
siRNA to Hoxc6.  These stable cells are designated 
BON-Flag control, BON-Hoxc6-V1, BON-Hoxc6-
V2, BON-si Hoxc6, and two independent clones of 
each construct was analyzed.  The pCMV FLAG-tag 
expression vector (Invitrogen) with the coding region 
of the human Hoxc6 variant 1 (V1) (NM_004503) or 
variant 2 (V2) (NM_153693) inserted between the 
BamHI and XhoI sites was transfected into BON1 
cells.  The cDNA of Hoxc6 V1 and V2 were a kind 
gift of Dr. Carlos Moreno (Emory University, At-
lanta) 13.  The N191Q mutation in Hoxc6 V1 and 
N109Q mutation in Hoxc6 V2 (AAC -> CAG) in 
the homeodomain 14 was introduced using the Quik 
Change IIXL Site-Directed Mutagenesis Kit (Strata-
gene).  The siRNA against Hoxc6 was made using 
pSR-neo vectors (Oligoengine, Seattle, WA).  The 
oligonucleotides were inserted between the BglII 
and HindIII sites to produce short hairpin RNA. 
Two different sequences derived from human Hoxc6 
mRNA (5’-GGGAAAAUUACAAAAAGAG-3’, 5’- 
GCGAAUGAAUUCGCACAGU-3’), common to 
Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth
19
both variant 1 and variant 2, were selected.  For con-
trol siRNA, we used the sequence 5’-GCGCGCTTT-
GTAGGATTCG-3’ that does not correspond to any 
known human gene.  The stable transfected cells 
were selected in 200 µg/ml geneticin (GIBCO) for 
14 days, and clones were screened for Hoxc6 stable 
expression by Western Blotting using ANTI-FLAG 
M2 (Sigma) and for Hoxc6 silencing by q-PCR. 
The cells were maintained in a 1:1 mixture of F12 
and DMEM (Cellgro) with 10% fetal bovine serum 
(Cellgro) supplemented with 1% penicillin/strepto-
mycin (Invitrogen) in 5% CO2 at 37°C.
Proliferation assay
The stable cells were plated in 96-well plates 
(1,500–3,000 cells per well). Proliferation of cells 
was measured by a colorimetric assay using the 
CellTiter 96 aqueous one solution cell proliferation 
assay kit (Promega) on day 1, 3, and 7 after plat-
ing.
Luciferase reporter assay
One day after plating the cells in a 12 well plate, 
0.25 µg of an AP-1 luciferase reporter construct that 
contains 4 consensus AP-1 binding sites and 5 ng 
of the pRL-CMV Renilla vector (Promega) were 
co-transfected using Lipofectamine 2000 (Invitro-
gen).  Luciferase activity was measured with the 
Dual Luciferase Reporter Assay System (Promega) 
48 hours after transfection.
Western Blotting and Immunoprecipitation
Cells were lysed in chilled lysis buffer (Cell 
Signaling) supplemented with proteinase inhibitor 
(PSC, Roche).  15-20 ug protein lysate were re-
solved on 4-12% NuPAGE Bis-Tris polyacrylamide 
gels (Invitrogen) and transferred to polyvinylidene 
difluoride membranes (Millipore).  Nuclear extracts 
were isolated using NE-PER kit (Pierce). The blots 
were probed with Flag and b-Actin (Sigma) antibod-
ies. Immunoreactive proteins were visualized using 
Western Lighting Chemiluminescence Reagent Plus 
(Perkin Elmer Life Sciences).
Nuclear extracts were prepared using the NE-
PER Nuclear and Cytoplasmic Extraction Reagents 
(PIERCE).  300 µg of nuclear proteins were incubat-
ed with ANTI-FLAG M2 beads (Sigma) overnight 
at 4°C.  The beads were washed 3 times with RIPA 
buffer (Boston BioProducts) for 5 min, and were 
boiled in NuPAGE SDS Sample Buffer (Invitrogen) 
for 10 min.  The samples were run on NuPAGE 
4-12% Bis-Tris Gels (Invitrogen) and detected by 
Western blotting using antibodies against JunD 
(sc-74, Santa Cruz) and Flag (ANTI-FLAG M2, 
Sigma).  The expression levels of JunD and Hoxc6 
(FLAG) in the samples were confirmed by Western 
Blotting using 10 µg of nuclear protein.
Statistical analysis
Statistical differences were analyzed by the stu-
dent’s t-test, and p-values <0.05 were considered 
statistically significant.
Results
Hoxc6 stimulates cellular proliferation of BON1 
cells in vitro
Because Hoxc6 was significantly upregulated 
in carcinoids, we focused our attention on this 
gene.  To determine the functional consequences of 
Hoxc6 expression in BON1 carcinoid cells, stable 
cell lines were generated in which either Hoxc6-V1 
or Hoxc6-V2 was overexpressed (Figure 1).  Two 
independent clones of each construct were analyzed. 
In vitro growth assays revealed that overexpression 
of variant 1 was associated with a 74% (clone #3, 
p<0.01) to 92% (clone #17, p<0.01) increase in cell 
number compared to control transfected cells at 7 
days (Figure 2).  Similarly, overexpression of variant 
2 was associated with a 68% (clone #3, p<0.01) to 
109% (clone #2, p<0.01) increase in cell number 
(Figure 2).  
To verify this effect, BON1 cells were gener-
ated that stably expressed an siRNA to endogenous 
Hoxc6.  Wild-type BON1 cells express low levels of 
Hoxc6.  The siRNA sequence utilized is common to 
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both variants and therefore targets both Hoxc6 tran-
scripts.  The silencing efficiency of two independent 
siRNA constructs to Hoxc6 is shown in Figure 3. 
In BON-siHoxc6#1 cells, levels of Hoxc6-V1 were 
suppressed to 16% of baseline and Hoxc6-V2 levels 
to 18% of baseline.  Similarly, in BON-siHoxc6#3 
cells, levels of Hoxc6-V1 were suppressed levels to 
18% of baseline and levels of Hoxc6-V2 to 14% of 
baseline.  When compared to BON1 cells expressing 
a control siRNA, there was a 43% decrease in the 
number of BON-siHoxc6#1 cells and 49% decrease 
in the number of BON-siHoxc6#3 cells at 7 days 
(Figure 2).  Thus, Hoxc6 can regulate the prolifera-
tion of BON1 carcinoid cells in vitro.  
Figure 1 Hoxc6 expression in BON1 carcinoid cells
Stable cell lines were generated in which either Flag tagged Hoxc6 variant 1 or Hoxc6 variant 2 was expressed.  Two indepedent 
clones of each construct were analyzed.  Expression was confirmed by western blotting for Flag.  Vector = BON1 cells stably 
expressing an empty Flag vector. 
Figure 2 Hoxc6 stimulates proliferation of BON1 cells in vitro
Proliferation of BON1 cells stably expressing Hoxc6 variant 1 (Hoxc6V1#3, Hoxc6V1#17), Hoxc6 variant 2 (Hoxc6V2#2, 
Hoxc6V2#3), or siRNA to Hoxc6 (siHoxc6#1, siHoxc6#3) was measured by a colorimetric assay on days 1, 3, and 7 after plat-
ing. 
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Hoxc6 enhances signaling through the AP-1 path-
way
To determine the mechanism through which 
Hoxc6 may control cellular proliferation, we tested 
the consequences of Hoxc6 overexpression on the 
AP-1 signaling pathway that is frequently activated 
in human malignancies.  An earlier report suggested 
that Hoxb4 can enhance signaling through the AP-1 
pathway by upregulating the expression of Jun-B 
and Fra-1 in Rat-1 cells 18.  AP-1 is a heterodimeric 
transcription factor that is a downstream target of 
multiple oncogenes including Ras, and it can regu-
late the expression of many genes critical for cellular 
growth 19.  A consensus AP-1 luciferase reporter con-
struct was introduced into BON1 cells that stably 
overexpressed either Hoxc6 variant 1 or variant 2. 
Compared to control BON1 cells, there was a 2.1 
to 3.0 fold (p<0.01) increase in AP-1 reporter activ-
ity in BON-Hoxc6-V1 cells, and a 2.1 to 2.8 fold 
(p<0.01) increase in BON-Hoxc6-V2 cells (Figure 
4a).  This induction was observed in two independent 
clones.  Similarly, in BON1 cells with Hoxc6 stably 
knocked-down, there was a 70% reduction (p<0.01) 
in AP-1 reporter activity in BON-siHoxc6#1 cells 
and a 66% reduction (p<0.01) in BON-siHoxc6#3 
cells (Figure 4b).  Thus, Hoxc6 can enhance signal-
ing through the AP-1 pathway.   
Regulation of JunD expression by Hoxc6
In BON1 cells stably overexpressing Hoxc6, there 
was a modest increase in JunD mRNA levels.  In 
BON-Hoxc6-V1 cells, there was a 2.23 fold increase 
(p<0.05) in JunD mRNA levels, but only a 1.56 fold 
increase (p=0.09) in BON-Hoxc6-V2 cells.  In cells 
stably expressing Hoxc6 siRNA, there was a 35% 
decrease (p=0.07) in JunD mRNA levels.  These 
findings suggest that Hoxc6 may regulate the ex-
pression of JunD, but that the level of induction is 
modest. 
Hoxc6 physically interacts with JunD through its 
homeodomain
The effects of Hoxc6 on expression of JunD were 
relatively modest, and we were curious whether there 
may be additional mechanisms controlling AP-1 
activity by Hoxc6.  A physical interaction between 
the yeast homeodomain protein Hex and c-Jun has 
been previously described, and Helix III of the Hex 
homeodomain mediated this interaction 14.  Because 
c-Jun was not involved in the functional activation of 
AP-1 by Hoxc6, we determined whether Hoxc6 may 
instead interact with JunD.  Immunoprecipitation 
Figure 3 The silencing efficiency of Hoxc6 knock down stable cell lines
Vectors expressing si RNA against Hoxc6 were stably transfected in BON1 cells.  The silencing efficiency of Hoxc6 knock 
down stable cell lines was shown by quantitative PCR for Hoxc6 variant 1 and variant 2.  The results are normalized to values 
from cells expressing a control siRNA. 
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of Hoxc6 from BON1 cells stably overexpressing 
Hoxc6 followed by immunoblotting with a JunD 
antibody revealed a specific interaction between 
endogenous JunD and both Hoxc6 variants (Figure 
5).  
To test whether this interaction was mediated by 
Helix III of the homeodomain, a point mutation 
was introduced in the Hoxc6 construct.  There is 
a conserved asparagine residue in Helix III of Hex 
that was previously demonstrated to be essential 
for its interaction with c-Jun 14.  This asparagine 
residue was selectively mutated in both Hoxc6 vari-
ants (N191Q in variant 1, designated mHoxc6-V1, 
and N109Q in variant 2, designated mHoxc6-V2). 
Figure 4b
A consensus AP-1 luciferase reporter construct was introduced into BON1 cells stably expressing siRNA to Hoxc6 (siHoxc6#1, 
siHoxc6#3).  The results shown are the ratio of AP-1 luciferase activity in these cells relative to those expressing vector control.  
Figure 4a Hoxc6 enhances signaling through the AP-1 pathway
A consensus AP-1 luciferase reporter construct was introduced into BON1 cells stably expressing Hoxc6 variant 1 (Hoxc6V1#3, 
Hoxc6V1#17), Hoxc6 variant 2 (Hoxc6V2#2, Hoxc6V2#3). The results shown are the ratio of AP-1 luciferase activity in these 
cells relative to those expressing vector control. 
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Immunoprecipitation-western studies revealed that 
both of these Hoxc6 mutants failed to interact with 
JunD (Figure 5).
To verify that Hoxc6 formed a complex with AP-1 
that physically bound to DNA, a DNA-precipitation 
assay was performed.  Nuclear extracts from BON1 
cells overexpressing either Hoxc6-V1 or Hoxc6-V2 
were incubated with a biotinylated AP-1 consensus 
element probe, and the AP-1 probe was precipitated 
with streptavidin beads.  Precipitated proteins were 
separated on an acrylamide gel, and immunoblot-
ting for Hoxc6 was performed.  In control cells, no 
Hoxc6 was identified in the precipitated complex. 
However, an interaction between Hoxc6 and the 
AP-1 probe was identified in extracts from cells 
overexpressing either wild-type Hoxc6 variant 1 or 
variant 2.  In contrast, when cells expressed mutant 
Hoxc6 (mHoxc6-V1 or mHoxc6-V2), no interaction 
with the AP-1 complex was observed (Figure 5). 
Thus, Hoxc6 directly binds to the AP-1 complex 
on DNA, and this interaction is mediated by the 
homeodomain of Hoxc6.
Mutant Hoxc6 inhibits AP-1 activity and cellular 
growth 
The functional effects of the interaction between 
Hoxc6 and AP-1 were verified by expressing the mu-
tant Hoxc6 that fails to interact with JunD.  In BON1 
cells expressing either mHoxc6-V1 or mHoxc6-V2, 
there was a 57% (p<0.01) to 51% (p<0.01) reduction 
of AP-1 reporter activity, respectively, indicating that 
this Hoxc6 mutant can inhibit AP-1 activity.  The 
growth rate of BON1 cells that stably expressed 
mHoxc6 was then measured.  In cells expressing 
either mHoxc6-V1 or mHoxc6-V2, there was a 55% 
to 50% (both p<0.01) reduction in cell number at 7 
days, respectively (Figure 6).  Thus, mutant forms 
of Hoxc6 that cannot interact with JunD can inhibit 
AP-1 activity as well as cellular growth.  
Discussion
Intestinal carcinoid tumors remain a fascinating 
clinical entity.  Unfortunately, the therapeutic op-
tions for advanced disease are very limited 20.  The 
poor understanding of the molecular genetic altera-
tions that underlie these tumors has hindered the 
search for new therapies.  Defining the key facets 
of the molecular circuitry of these unique tumors is 
an important prerequisite to the rational design of 
novel targeted approaches.  The current studies have 
identified a new molecular pathway in carcinoid 
Figure 5 Hoxc6 interacts with JunD through its homeodomain
Immunoprecipitation of Hoxc6 (Flag) from BON1 cells stably overexpressing Flag tagged-Hoxc6 followed by immunoblotting 
with a JunD antibody.  The mutant constructs have a N191Q mutation in Hoxc6-V1 and N109Q mutation in Hoxc6-V2 home-
odomain (AAC -> CAG).
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tumorigenesis that involves the Hoxc6 homeobox 
gene.   
HOX genes are critical regulators of cellular pro-
liferation and differentiation during development.  A 
link between deregulated expression of HOX genes 
and cancer has been observed in many tumor types, 
but no consistent mechanism of action has yet been 
defined.  Although HOX genes are homeodomain 
transcription factors that recognize a consensus 
TAAT motif, their functions in cancer appear to be 
far more diverse 10.  Overexpression of homeobox 
genes can induce cellular transformation 25, 26, and 
some of this may be mediated by the upregulation of 
genes normally targeted during development, such 
as fibroblast growth factor 11.  However, other non-
transcriptional functions have been defined as well. 
For example, Hox11 can control the G2 cell-cycle 
checkpoint through its physical interaction with 
protein phosphatases PP2A and PP4 27.  
Our studies have identified a role for Hoxc6 in 
carcinoid tumorigenesis.  In the developing mouse 
embryo, Hoxc6 is expressed in the spinal cord, 
prevertebrae, kidney, and selected compartments of 
lung, stomach, and intestine 28.  In human tumors, 
overexpression of Hoxc6 has thus far been impli-
cated in the pathogenesis of prostate cancer 12, 13.  In 
prostate cancer, Hoxc6 appears to regulate neutral 
endopeptidase (NEP) and insulin-like growth factor 
binding protein-3 (IGFBP-3), both of which may in 
turn regulate apoptosis 13. 
In carcinoid tumors, Hoxc6 appears to function 
in a novel manner as a potent enhancer of signal-
ing through the AP-1 pathway, and this is mediated 
through JunD.  There are at least 2 distinct mecha-
nisms for this effect.  First, Hoxc6 can modestly 
upregulate JunD.  In addition, Hoxc6 can physically 
interact with JunD to enhance transcriptional activa-
tion through AP-1, and this interaction is mediated 
by the homeodomain of Hoxc6.  This contrasts with 
the yeast Hex transcription factor.  Hex also binds to 
AP-1 proteins through the homeodomain, but Hex 
functions to inhibit AP-1 activity.  This inhibitory 
activity is strengthened when a Hex binding site is 
also present in the promoter 14.  Thus, homeobox 
proteins may be important regulators of AP-1 activ-
ity, and Hoxc6 is an enhancer of AP-1 activity in 
carcinoid tumors.  
The AP-1 transcription factor regulates a diverse 
Figure 6 Mutant Hoxc6 inhibits cellular growth
Proliferation of BON1 cells stably expressing mutant Hoxc6 variant 1 or variant 2 was measured by a colorimetric assay on days 1, 
3, and 7 after plating.  
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set of cellular processes, and these effects are not 
only cell-specific but also dependent upon the bal-
ance of specific Fos and Jun proteins.  In contrast to 
c-Jun, the precise functions of JunD remain incom-
pletely described 19.  Depending upon the particular 
environment, JunD can exhibit both pro-proliferative 
as well as growth inhibitory properties 29.  The tu-
mor suppressor protein menin has been reported to 
interact with JunD, and it can suppress the growth 
promoting activity of JunD 30, 31.  In contrast, Hoxc6 
appears to function in an opposing manner to regu-
late JunD.  The relationship between Hoxc6 and 
menin in carcinoid tumors remains uncertain.  Stud-
ies in murine embryonic tissue have demonstrated 
a strong induction of Hoxc6 by menin 6.  However, 
menin mRNA levels in carcinoid tumors and BON1 
cells were very low, and overexpression of menin in 
BON1 cells did not induce Hoxc6 gene expression 
(data not shown).  Thus, menin does not appear to 
be an important regulator of Hoxc6 expression in 
adult neuroendocrine tissues.  
The selective induction of Hoxc6 in carcinoid 
tumors but not pancreatic neuroendocrine tumors, 
normal pancreas, or normal intestine suggests that 
there are likely to be tissue-specific mechanisms 
that regulate Hoxc6 expression in carcinoids.  In 
tumor pathogenesis, Hoxc6 may also play a role 
in specifying the neuroendocrine phenotype.  This 
selective upregulation also suggests that Hoxc6 may 
be an important therapeutic target.  Potential strate-
gies include inhibition of Hoxc6 directly, inhibition 
of the interaction between Hoxc6 and JunD, or in-
hibition of the AP-1 signaling pathway in general. 
Regardless, these observations have revealed a new 
pathway that underlies the molecular pathogenesis 
of carcinoid tumors.  
References
1. Modlin IM, Sandor A. An analysis of 8305 cases of 
carcinoid tumors. Cancer 1997; 79: 813-29.
2. Schnirer, II, Yao JC, Ajani JA. Carcinoid--a compre-
hensive review. Acta Oncol 2003; 42: 672-92.
3. Chandrasekharappa SC, Guru SC, Manickam P, Olufe-
mi SE, Collins FS, Emmert-Buck MR, Debelenko LV, 
Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang 
Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, 
Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, 
Burns AL, Marx SJ. Positional cloning of the gene for 
multiple endocrine neoplasia-type 1. Science 1997; 
276: 404-7.
4. Duerr EM, Chung DC. Molecular genetics of neuroen-
docrine tumors. Best Pract Res Clin Endocrinol Metab 
2007; 21: 1-14.
5. Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, 
Hickman AB, Cerrato A, Rice TS, Moore JB, Rao S, Ji 
Y, Mateo C, Libutti SK, Oliver B, Chandrasekharappa 
SC, Burns AL, Collins FS, Spiegel AM, Marx SJ. 
Menin molecular interactions: insights into normal 
functions and tumorigenesis. Horm Metab Res 2005; 
37: 369-74.
6. Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland 
TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, 
Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, 
Hess JL, Meyerson M. Menin associates with a tritho-
rax family histone methyltransferase complex and with 
the hoxc8 locus. Mol Cell 2004; 13: 587-97.
7. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-
Rosen O, Meyerson M, Cleary ML. The menin tumor 
suppressor protein is an essential oncogenic cofactor 
for MLL-associated leukemogenesis. Cell 2005; 123: 
207-18.
8. Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, 
McLean GW, Xiong Y, Meyerson M, Kim SK. Menin 
regulates pancreatic islet growth by promoting histone 
methylation and expression of genes encoding p27Kip1 
and p18INK4c. Proc Natl Acad Sci U S A 2005; 102: 
14659-64.
9. Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-
Rosen O, Dou Y, Schnepp RW, Krankel C, Livolsi VA, 
Gibbs D, Hua X, Roeder RG, Meyerson M, Hess JL. 
Menin and MLL cooperatively regulate expression of 
cyclin-dependent kinase inhibitors. Proc Natl Acad Sci 
U S A 2005; 102: 749-54.
10. Abate-Shen C. Deregulated homeobox gene expres-
sion in cancer: cause or consequence? Nat Rev Cancer 
2002; 2: 777-85.
11. Care A, Silvani A, Meccia E, Mattia G, Stoppacciaro 
A, Parmiani G, Peschle C, Colombo MP. HOXB7 con-
stitutively activates basic fibroblast growth factor in 
melanomas. Mol Cell Biol 1996; 16: 4842-51.
26
12. Miller GJ, Miller HL, van Bokhoven A, Lambert JR, 
Werahera PN, Schirripa O, Lucia MS, Nordeen SK. 
Aberrant HOXC expression accompanies the malig-
nant phenotype in human prostate. Cancer Res 2003; 
63: 5879-88.
13. Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim 
SD, Laycock N, Amin MB, Carney JK, Marshall FF, 
Petros JA, Moreno CS. Loss of HOXC6 expression 
induces apoptosis in prostate cancer cells. Oncogene 
2005; 24: 188-98.
14. Schaefer LK, Wang S, Schaefer TS. Functional interac-
tion of Jun and homeodomain proteins. J Biol Chem 
2001; 276: 43074-82.
15. Smyth GK. Linear models and empirical bayes meth-
ods for assessing differential expression in microarray 
experiments. Stat Appl Genet Mol Biol 2004; 3: Article 
3.
16. Benjamini Y, Hochberg Y. Controlling the false discov-
ery rate: a practical and powerful approach to multiple 
testing. J. R. Stat. Soc., B 1995; 57: 289-300.
17. Chariot A, Castronovo V, Le P, Gillet C, Sobel ME, 
Gielen J. Cloning and expression of a new HOXC6 
transcript encoding a repressing protein. Biochem J 
1996; 319 (Pt 1): 91-7.
18. Krosl J, Sauvageau G. AP-1 complex is effector of 
Hox-induced cellular proliferation and transformation. 
Oncogene 2000; 19: 5134-41.
19. Shaulian E, Karin M. AP-1 as a regulator of cell life 
and death. Nat Cell Biol 2002; 4: E131-6.
20. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro 
MD. Current status of gastrointestinal carcinoids. Gas-
troenterology 2005; 128: 1717-51.
21. Thomas RP, Hellmich MR, Townsend CM, Jr., Evers 
BM. Role of gastrointestinal hormones in the prolif-
eration of normal and neoplastic tissues. Endocr Rev 
2003; 24: 571-99.
22. Kidd M, Modlin IM, Eick GN, Camp RL, Mane SM. 
Role of CCN2/CTGF in the proliferation of Mastomys 
enterochromaffin-like cells and gastric carcinoid devel-
opment. Am J Physiol Gastrointest Liver Physiol 2007; 
292: G191-200.
23. Bullock BP, McNeil GP, Dobner PR. Synergistic in-
duction of neurotensin gene transcription in PC12 cells 
parallels changes in AP-1 activity. Brain Res Mol Brain 
Res 1994; 27: 232-42.
24. Moritani NH, Kubota S, Eguchi T, Fukunaga T, Ya-
mashiro T, Takano-Yamamoto T, Tahara H, Ohyama K, 
Sugahara T, Takigawa M. Interaction of AP-1 and the 
ctgf gene: a possible driver of chondrocyte hypertrophy 
in growth cartilage. J Bone Miner Metab 2003; 21: 
205-10.
25. Aberdam D, Negreanu V, Sachs L, Blatt C. The onco-
genic potential of an activated Hox-2.4 homeobox gene 
in mouse fibroblasts. Mol Cell Biol 1991; 11: 554-7.
26. Maulbecker CC, Gruss P. The oncogenic potential 
of deregulated homeobox genes. Cell Growth Differ 
1993; 4: 431-41.
27. Kawabe T, Muslin AJ, Korsmeyer SJ. HOX11 interacts 
with protein phosphatases PP2A and PP1 and disrupts 
a G2/M cell-cycle checkpoint. Nature 1997; 385: 
454-8.
28. Sharpe PT, Miller JR, Evans EP, Burtenshaw MD, 
Gaunt SJ. Isolation and expression of a new mouse ho-
meobox gene. Development 1988; 102: 397-407.
29. Weitzman JB, Fiette L, Matsuo K, Yaniv M. JunD pro-
tects cells from p53-dependent senescence and apopto-
sis. Mol Cell 2000; 6: 1109-19.
30. Agarwal SK, Guru SC, Heppner C, Erdos MR, Col-
lins RM, Park SY, Saggar S, Chandrasekharappa SC, 
Collins FS, Spiegel AM, Marx SJ, Burns AL. Menin 
interacts with the AP1 transcription factor JunD and 
represses JunD-activated transcription. Cell 1999; 96: 
143-52.
31. Agarwal SK, Novotny EA, Crabtree JS, Weitzman JB, 
Yaniv M, Burns AL, Chandrasekharappa SC, Collins 
FS, Spiegel AM, Marx SJ. Transcription factor JunD, 
deprived of menin, switches from growth suppressor to 
growth promoter. Proc Natl Acad Sci U S A 2003; 100: 
10770-5.
